Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 345-355

  Westphal, Kristin ^a,b,c,d   Weinbrenner, Anita ^a,b,c,d   Zschiesche, Michael ^a,b,c,d   Franke, Gerd ^a,b,c,d   Knoke, Manfred ^a,b,c,d   Oertel, Reinhard ^a,b,c,d   Fritz, Peter ^a,b,c,d   Von Richter, Oliver ^a,b,c,d   Warzok, Rolf ^a,b,c,d   Hachenberg, Thomas ^a,b,c,d   Kauffmann, Hans Martin ^a,b,c,d   Schrenk, Dieter ^a,b,c,d   Terhaag, Bernd ^a,b,c,d   Kroemer, Heyo K ^a,b,c,d   Siegmund, Werner ^a,b,c,d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG RELEASE; DRUG TRANSPORT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTESTINE MUCOSA; INTESTINE SECRETION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STEADY STATE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BLOTTING, WESTERN; DUODENUM; ENDOSCOPY, DIGESTIVE SYSTEM; ENZYME INDUCTION; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; RNA, MESSENGER; UP-REGULATION;

EID: 0033753435     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.109797     Document Type: Article

References (47)

1. Cardiovascular news: Withdrawal of Posicor from market
2. Metabolism of digoxin, digoxigenin, digitoxosides and digoxigenin in human hepatocytes and liver microsomes
3. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans
4. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs
5. Digoxin-verapamil interaction
6. Quinidine reduces biliary clearance of digoxin in man
7. Interaction between digoxin and propafenone
8. Itraconazole decreases renal clearance of digoxin
9. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
10. Inhibition of the intestinal digoxin absorption and exsorption by quinidine
11. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
12. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
13. Inhibition of P-glycoprotein-mediated drug transport
14. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1)
15. 1)
16. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues
17. Tissue distribution of P-glycoprotein encoded by a multidrug-resistance gene as revealed by a monoclonal antibody, MRK16
18. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
19. P-glycoprotein expression and function in circulating blood cells from normal volunteers
20. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1 a P-glycoprotein
21. The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein
22. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo
23. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
24. 1-adrenoceptor antagonist talinolol in man
25. Elucidation of the structure of talinolol metabolites in man: Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
26. Identification of talinolol metabolites in urine of man, dog, rat and mouse after oral administration by high-performance liquid chromatography-thermospray tandem mass spectrometry
27. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans
28. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
29. Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans
30. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
31. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
32. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma
33. Immunoenzyme labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)
34. Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines
35. Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients
36. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: Immunohistochemical characterization of cytochrome P 450 3A and glutathione-S-transferase
37. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
38. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
39. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers
40. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
41. Pharmacokinetics of oral and intravenous rifampin during chronic administration
42. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
43. In vivo induction of liver p-glycoprotein expression by xenobiotics in monkeys
44. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
45. Modulation of P-glycoprotein expression by cytochrome P4503A inducers in male and female rat livers
46. Expression of p-glycoprotein 170 in nasal mucosa may be increased with topical steroids
47. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells